Sp1287
VELSIPITY (ETRASIMOD): COME LEARN ABOUT AN RX TREATMENT OPTION FROM PFIZER
Date
May 19, 2024
Presenters
Tracks
Related Products
SURVODUTIDE REDUCES LIVER FAT CONTENT, TRANSAMINASES, AND FIBROSIS MARKERS WITH GOOD SAFETY PROFILE IN PEOPLE WITH METABOLIC DYSFUNCTION-ASSOCIATED STEATOHEPATITIS (MASH): AN INTERIM ANALYSIS OF A RANDOMIZED, DOUBLE-BLIND, PLACEBO-CONTROLLED PHASE 2 TRIAL
BACKGROUND: Survodutide is a novel glucagon receptor/glucagon-like peptide-1 receptor dual agonist under investigation for treatment in advanced liver disease associated with metabolic dysfunction-associated steatohepatitis (MASH), the most severe form of metabolic dysfunction-associated steatotic…
TRENDS IN RACIAL DISPARITIES IN SURGICAL CARE FOR IBD PATIENTS
Socioeconomic status (SES) has proven significant impact on colorectal cancer (CRC) outcomes. Lower SES has correlated with increased comorbidities, risk of postoperative complications, and inadequate adherence to treatment guidelines…
TOP 3-5 TIPS FOR SURVIVING THE FIRST YEARS IN CLINICAL PRACTICE
The purpose of this session is to provide early career and trainee gastroenterologist with tips and strategies for having successful first few years in clinical practice…
THE IMPORTANCE OF LONG-TERM CLINICAL OUTCOMES IN BIO-NAIVE PATIENTS
This case based presentation will highlight the importance of long-term clinical outcomes in bio-naive patients across both Crohn's disease and ulcerative colitis. Sponsored by Janssen Biotech, Inc…
